Lipodystrophy and metabolic complications

HIV and statins: REPRIEVE studies at CROI 2024

CROI 2024: HIV studies with semaglutide: significant benefits but limited access for treatment and research

US guidelines recommend earlier use of statins in people living with HIV

UK surveys on access to New-Fill for facial lipoatrophy

>10% weight gain during first two years of ART linked to double the risk of cardiometabolic disease

IAS 2023: Metabolic and weight changes using GLP-1 agonists in people living with HIV: need for more data

Overview of weight gain, integrase inhibitors and ART

Selected webcasts from BHIVA 2023

IAS 2022: Metabolic complications of newer HIV drugs in older people

INSTIs and cardiovascular events in the RESPOND cohort: early increase at six months normalises after two years

Weight changes on ART and how to lose weight successfully

Tesamorelin for NAFLD in people living with HIV

Weight gain and metabolic syndrome with dolutegravir and TAF: results from the ADVANCE trial

Over half of mostly black US HIV group has NAFLD – and many have NASH

Type 2 diabetes is often undermanaged in HIV positive people

INSTI and weight gain: reports from CROI 2019

9th International Workshop on HIV and Ageing

Boosted darunavir is associated with higher cardiovascular risk in D:A:D study, but not atazanavir

Reducing risk of myocardial infarction (MI) in HIV positive people

Low HDL cholesterol is main lipid abnormality in HIV+/HIV- comparison

No association between bone mineral density and lipodystrophy in women receiving antiretroviral therapy

Intestinal microflora and low grade metabolic inflammation

Complex connections between bone and fat metabolism

UK studies on bone health: increasedfracture rates reported in HIV-positive people

12th International Workshop on Adverse Drug Reactions and Co-Morbidities in HIV, 4-–6 November 2010, London

Bio-Alcamid associated with unacceptable risk of complications: no longer recommended as a treatment for facial lipoatrophy

Age raises fracture risk more in HIV-positive people

FDA approves tesamorelin for reduction of central fat accumulation

Tesamorelin for reduction of central fat accumulation: regulatory decision delayed in the US

75% HIV-positive children have insufficient levels of Vitamin D

High rates of osteopenia and osteoporosis: importance of DEXA monitoring

ACTG 5205: atazanavir/ritonavir vs efavirenz in treatment naive patients

Clinical benefits of stopping smoking: CVD and CHD risk returns to that of ‘previous smoker’ in HIV-positive people within three years

Vitamin D deficiencies in HIV management

Central fat accumulation remains a significant problem in patients starting HAART after 2005 with higher incidence in women compared to men

Gender and race differences in lipodystrophy symptoms

Visceral adipose tissue returns to baseline after stopping therapeutic intervention with rHGH

Raltegravir body composition study: 48-week DEXA results

Lipid and metabolic changes with ARV combinations

Haemoglobin A1c (HbA1c) may underestimate glycaemia in patients with diabetes on HIV therapy

Statin use in HIV-positive patients

New-fill used to treat lipoatropy in feet

Tesamorelin (TH9507) reduces abdominal fat in patients with HIV-related lipodystrophy: 52 week results

Growth hormone release factor (TH9507) reduces central fat adiposity

d4T associated with significantly increased risk of type-2 diabetes mellitus

Switching from PIs to NNRTIs has similar effect on TC/HDL ratio as use of lipid lowering drugs in the management of dyslipidaemia

The role of the metabolic syndrome in HIV

Effect of lifestyle modification on risk factors for cardiovascular disease and metabolic syndrome

Pioglitazone reduces peripheral lipoatrophy and improves adipokines without reducing visceral fat

Interventions for the management of lipodystrophy and metabolic complications

Uridine supplement reverses thymidine-induced lipoatrophy

Pravastatin increases limb fat in HIV-positive patients with hypercholesterolaemia

Evidence that facial fat can return after switching from either d4T or AZT, to abacavir or tenofovir

Niacin has beneficial effect on lipids but no reduction in abdominal fat

Gluteal implants used to replace lost buttock fat

Omega-3 supplement effective to reduce triglycerides

Switch to tenofovir from AZT or d4T improves fat loss and improves lipid parameters compared to abacavir

Continued use of a thymidine analogue may limit benefit from rosiglitazone when used to treat lipoatrophy

Nucleoside analogue-related mitochondrial toxicity and link to lipoatrophy: effect of non-thymidine analogues abacavir and tenofovir

Potential for uridine to treat mitochondrial toxicity: still only in vitro data

rHGH reduces central fat accumulation in adolescent lipodystrophy

Pravastatin improves lipid profiles but not endothelial function

Treatment interruptions improve lipids within four weeks: IL-2 has no metabolic effect

Improvement of lipids following switch to tenofovir

Restorative treatments for HIV-associated lipoatrophy

Post navigation